Lista de obras - Tadeusz Pienkowski - Dominio Público Uruguay

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

artículo científico publicado en 2016

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

artículo científico publicado en 2008

A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer

artículo científico publicado en 2010

Abstract P3-10-24: Fibroblast Growth Factor Receptor 1 Amplification and Overexpression in Breast Cancer Tissue Microarrays Using Chromogenic In Situ Hybridization and Immunohistochemistry

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

artículo científico publicado en 2013

Adjuvant docetaxel for node-positive breast cancer

artículo científico publicado en 2005

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

artículo científico publicado en 2012

Adjuvant trastuzumab in HER2-positive breast cancer

artículo científico publicado en 2011

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer

artículo científico publicado en 2006

Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.

artículo científico publicado en 2009

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

artículo científico publicado en 2010

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

artículo científico publicado en 2011

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients

artículo científico publicado en 2012

Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients.

artículo científico publicado en 2013

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

scientific article published on 01 March 2019

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

artículo científico publicado en 2016

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial ⬇️

artículo científico publicado el 10 de enero de 2013

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

artículo científico publicado en 2017

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

artículo científico publicado en 2009

Breast cancer--selected aspects of systemic treatment

artículo científico publicado en 2014

Cancer epidemiology in Central, South and Eastern European countries.

artículo científico publicado en 2011

Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples.

artículo científico

Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study

artículo científico publicado en 1997

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

scientific article published on 24 June 2019

Corrigendum to “ONCOPOOL – A European database for 16,944 cases of breast cancer” [European Journal of Cancer 46 (2009) 56–71]

scholarly article published in European Journal of Cancer

Current perspective on smoking epidemics in Poland – statement the Polish Society of Public Health

artículo científico publicado en 2022

Delays in diagnosis and treatment of breast cancer: a multinational analysis.

artículo científico publicado en 2013

Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay.

artículo científico publicado en 2004

Detection of circulating cancer cells in peripheral blood as a prognostic factor in early breast cancer.

artículo científico publicado en 2005

Distribution of lymph node metastases in the malignant melanoma of the trunk

scientific article published on 01 January 1984

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

artículo científico publicado en 2003

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial

artículo científico publicado en 2009

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

artículo científico publicado en 2001

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

artículo científico publicado en 2012

Expression of HER2/neu in primary and metastatic breast cancer

artículo científico publicado en 2001

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

artículo científico publicado en 2010

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

article

Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines

artículo científico publicado en 2001

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials

artículo científico publicado en 2016

Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study

scientific article published on 28 June 2013

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

artículo científico publicado en 2015

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

artículo científico publicado en 2006

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

artículo científico publicado en 2013

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

artículo científico

Long-term survival in primary breast cancer: correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy.

artículo científico publicado en 2004

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

artículo científico publicado en 2005

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

artículo científico publicado en 2011

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

artículo científico publicado en 2010

ONCOPOOL - a European database for 16,944 cases of breast cancer.

artículo científico publicado en 2010

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

artículo científico publicado en 2013

Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy

artículo científico publicado en 2007

Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study

artículo científico publicado en 2006

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

artículo científico publicado en 2015

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

artículo científico publicado en 2012

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes

scientific article published on 09 August 2009

Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.

artículo científico publicado en 2004

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

artículo científico publicado en 2011

Preoperative chemotherapy in primarily inoperable cancer of the breast

artículo científico publicado el 1 de diciembre de 1991

Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer

artículo científico publicado en 2012

Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.

artículo científico publicado en 2002

Recovery of dendritic cell counts and function in peripheral blood of cancer patients after chemotherapy

artículo científico publicado en 2002

Reducing the global breast cancer burden: the importance of patterns of care research

artículo científico publicado en 2005

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

artículo científico publicado en 2019

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

artículo científico publicado en 2004

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

artículo científico publicado en 2014

Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.

artículo científico publicado en 2005

Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients.

artículo científico publicado en 2006

Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer

artículo científico publicado en 2010

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

scientific article published on 09 August 2012

The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives

artículo científico publicado en 2004

The treatment of metastasizing breast carcinoma using antiestrogens

artículo científico publicado en 1991

Topoisomerase 2α status in invasive breast carcinoma - comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluation

artículo científico publicado en 2014

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

artículo científico publicado en 2016

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE

scientific article published on 18 July 2019

Trastuzumab treatment in patients with breast cancer and metastatic CNS disease.

artículo científico publicado en 2009

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

artículo científico publicado en 2015

[Diagnosis and treatment of carcinoid meningitis: a challenge to the neurologist and oncologist]

scientific article published on 01 January 2003

[Early results of hormonal treatment of advanced breast cancer with aminoglutethimide]

artículo científico publicado en 1988

[Effectiveness of chemotherapy by the AVM protocol (adriamycin, vincristine and methotrexate) after unsuccessful treatment of patients with non-seminoma using PVB (cisplatin, vinblastine and bleomycin)]

artículo científico publicado en 1984

[Evaluation of tamoxifen in the treatment of female patients with advanced breast cancer]

scientific article published on 01 April 1985

[Evaluation of the results of treatment with medroxyprogesterone acetate (MPA) of patients with advanced breast cancer]

scientific article published on 01 July 1985

[Preliminary evaluation of the toxicity and effectiveness of chemotherapy using the VAB-6 protocol in the treatment of non-seminoma of the testis]

scientific article published on 01 January 1987

[Preliminary results of the treatment with aminoglutethimide of patients with advanced breast cancer]

[Recommendations of National Team of Cardiologic and Oncologic Supervision on cardiologic safety of patients with breast cancer. The prevention and treatment of cardiovascular complications in breast cancer. The Task Force of National Consultants in

artículo científico publicado en 2011

Lista de obras de Tadeusz Pienkowski

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer

Abstract P3-10-24: Fibroblast Growth Factor Receptor 1 Amplification and Overexpression in Breast Cancer Tissue Microarrays Using Chromogenic In Situ Hybridization and Immunohistochemistry

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

Adjuvant docetaxel for node-positive breast cancer

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

Adjuvant trastuzumab in HER2-positive breast cancer

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer

Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients

Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients.

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial ⬇️

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

Breast cancer--selected aspects of systemic treatment

Cancer epidemiology in Central, South and Eastern European countries.

Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples.

Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Corrigendum to “ONCOPOOL – A European database for 16,944 cases of breast cancer” [European Journal of Cancer 46 (2009) 56–71]

Current perspective on smoking epidemics in Poland – statement the Polish Society of Public Health

Delays in diagnosis and treatment of breast cancer: a multinational analysis.

Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay.

Detection of circulating cancer cells in peripheral blood as a prognostic factor in early breast cancer.

Distribution of lymph node metastases in the malignant melanoma of the trunk

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Expression of HER2/neu in primary and metastatic breast cancer

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials

Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

Long-term survival in primary breast cancer: correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy.

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

ONCOPOOL - a European database for 16,944 cases of breast cancer.

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy

Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes

Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

Preoperative chemotherapy in primarily inoperable cancer of the breast

Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer

Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.

Recovery of dendritic cell counts and function in peripheral blood of cancer patients after chemotherapy

Reducing the global breast cancer burden: the importance of patterns of care research

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.

Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients.

Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives

The treatment of metastasizing breast carcinoma using antiestrogens

Topoisomerase 2α status in invasive breast carcinoma - comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluation

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE

Trastuzumab treatment in patients with breast cancer and metastatic CNS disease.

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

[Diagnosis and treatment of carcinoid meningitis: a challenge to the neurologist and oncologist]

[Early results of hormonal treatment of advanced breast cancer with aminoglutethimide]

[Effectiveness of chemotherapy by the AVM protocol (adriamycin, vincristine and methotrexate) after unsuccessful treatment of patients with non-seminoma using PVB (cisplatin, vinblastine and bleomycin)]